Integra LifeSciences Completes Purchase of TEI Businesses
Plainsboro, N.J., devicemaker Integra LifeSciences has completed its $312 million cash acquisition of TEI Biosciences and TEI Medical.
The deal, originally announced June 28, complements and expands Integra’s reconstructive surgery and wound care product lines, including the diabetic foot ulcer market. It also adds about 125 sales personnel to the company’s existing sales force.
Integra expects revenues of $870 million to $885 million in 2015, according to a 2nd quarter earnings report. The forecast reflects a slight increase expected from the TEI deal.
TEI had sales of about $63.5 million in 2014, according to Integra.—Meg Bryant